Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty

To study the association of and polymorphisms and the clopidogrel response in Spanish peripheral artery disease patients following percutaneous transluminal angioplasty (PTA) and to perform a meta-analysis. 72 patients were recruited and 122 patients included in the meta-analysis. We evaluated the e...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2016-08, Vol.17 (12), p.1327-1338
Main Authors: Díaz-Villamarín, Xando, Dávila-Fajardo, Cristina Lucía, Martínez-González, Luis Javier, Carmona-Sáez, Pedro, Sánchez-Ramos, Jesús, Álvarez Cubero, María Jesús, Salmerón-Febres, Luis Miguel, Cabeza Barrera, Jose, Fernández-Quesada, Fidel
Format: Article
Language:English
Subjects:
Aged
Angioplasty
Atherosclerosis - genetics
Atherosclerosis - surgery
ATP Binding Cassette Transporter, Sub-Family B - genetics
Bioavailability
Cardiovascular disease
Clinical outcomes
Clopidogrel
Cytochrome
Cytochrome P-450 CYP2C19 - genetics
Enzymes
Female
Genes
Genetic markers
Genotype
Genotype & phenotype
Graft Occlusion, Vascular - epidemiology
Graft Occlusion, Vascular - genetics
Humans
Ischemia
Lower Extremity - blood supply
Male
Meta-analysis
Occlusion
percutaneous transluminal angioplasty
Peripheral Arterial Disease - drug therapy
Peripheral Arterial Disease - genetics
pharmacogenetics
Platelet Aggregation Inhibitors - therapeutic use
Polymorphism
Polymorphism, Genetic - genetics
Restenosis
SNP
Spain
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Treatment Outcome
Vascular diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study the association of and polymorphisms and the clopidogrel response in Spanish peripheral artery disease patients following percutaneous transluminal angioplasty (PTA) and to perform a meta-analysis. 72 patients were recruited and 122 patients included in the meta-analysis. We evaluated the effect of 3435 C>T, and and primary end point (restenosis/occlusion of the treated lesions) during 12 months after PTA. and/or TT patients were associated with primary end point (OR: 5.00; 95% CI: 1.75-14.27). The meta-analysis confirmed the association of and new atherothrombotic ischemic events (OR: 5.40; 95% CI: 2.30-12.70). The and polymorphisms could be genetic markers of cardiovascular events in peripheral artery disease patients following PTA treated with clopidogrel.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2016-0056